Metformin in the treatment of colorectal cancer and neuroendocrine tumours

Karolina Daniłowska; Natalia Picheta; Barbara I. Krupska; Anna Rudzińska; Oliwia Burdan; Katarzyna Szklener

doi:10.5114/wo.2024.142553

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2024
vol. 28

Send email

Copy url:

abstract:

Review paper

Metformin in the treatment of colorectal cancer and neuroendocrine tumours

Karolina Daniłowska

¹

,

Natalia Picheta

¹

,

Barbara I. Krupska

¹

,

Anna Rudzińska

¹

,

Oliwia Burdan

¹

,

Katarzyna Szklener

²

Student Academic Group at the Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland
Oncology and Chemotherapy Department, Independent Public Clinical Hospital no. 4, Lublin, Poland

Contemp Oncol (Pozn) 2024; 28 (2): 85–90

DOI: https://doi.org/10.5114/wo.2024.142553

Online publish date: 2024/08/23

View full text Get citation

PlumX metrics:

Colorectal cancer is being detected in increasingly younger age groups, and its incidence has been on the rise in recent years. Neuroendocrine tumors have also shown an increase in occurrence despite their rarity. Neuroendocrine tumors most commonly occur in the gastrointestinal tract and lungs. Therefore, new, better, and more effective treatment methods are being sought. Metformin, a drug commonly used in the treatment of type 2 diabetes, has demonstrated its ability to reduce the incidence and increase the efficacy of chemotherapy in colorectal cancer and neuroendocrine tumors. The biguanide works by inhibiting the mammalian target of rapamycin pathway, activating 5’AMP activated protein kinase, and reducing insulin-like growth factor 1. In studies conducted on human cells and xenografts, the drug has shown its positive effects in combating these tumors by reducing proliferation, slowing the growth of cancer cells, and inhibiting metastasis. The main goal of this review is to comprehensively summarize the current state of knowledge regarding metformin in the treatment of colorectal cancer and neuroendocrine tumors.

keywords:

colorectal cancer, neuroendocrine tumours, metformin, metformin in the treatment of colorectal cancer, metformin in the treatment of neuroendocrine tumours

Metformin in the treatment of colorectal cancer and neuroendocrine tumours

Karolina Daniłowska 1 , Natalia Picheta 1 , Barbara I. Krupska 1 , Anna Rudzińska 1 , Oliwia Burdan 1 , Katarzyna Szklener 2

colorectal cancer, neuroendocrine tumours, metformin, metformin in the treatment of colorectal cancer, metformin in the treatment of neuroendocrine tumours

Karolina Daniłowska

¹

,

Natalia Picheta

¹

,

Barbara I. Krupska

¹

,

Anna Rudzińska

¹

,

Oliwia Burdan

¹

,

Katarzyna Szklener

²